Molecular Profiling of Immunotherapeutic Resistance

Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition

Volumn , Issue , 2013, Pages 373-394

  Bedognetti, Davide ^a,b   Wang, Ena ^a   Sato Matsushita, Marimo ^a,c   Marincola, Francesco M ^a,d   Ascierto, Maria Libera ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF TOKYO   (Japan)

^d SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Adoptive therapy; Bedside to bench and back; Biomarker; CCR5; Chemokine; CXCR3; Gene expression profiling; Gene signature; High throughput technology; Immunologic constant of rejection; Immunotherapy; Interferon signaling; Interleukin 2; Microarray; Vaccine therapy

Indexed keywords

EID: 84902216759     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394296-8.00023-3     Document Type: Chapter

References (130)

1. Lindahl S., Marincola F.M. Translational medicine, Encyclopedia Britannica 2012, in press.
2. Marincola F.M. In support of descriptive studies; relevance to translational research. J Transl Med 2007, 5:21.
3. Marincola F.M. The trouble with translational medicine. J Intern Med 2011, 270(2):123-127.
4. Marincola F.M. Translational Medicine: A two-way road. J Transl Med 2003, 1(1):1.
5. Nussenblatt R.B., Marincola F.M., Schechter A.N. Translational medicine-doing it backwards. J Transl Med 2010, 8:12.
6. BB&B -Bedside to Bench & Back Lecture Series [cited; Available from. http://www.nhlbi.nih.gov/resources/chi/meetings/bedside.htm.
7. Achinstein P. General Introduction. Science Rules: A Historical Introduction to Scientific Methods 2004, Johns Hopkins University Press, p. 1-5.
8. Popper K. The Logic of Scientific Discovery 2002, Routledge Classics, New York, NY.
9. Coley W.B. II. Contribution to the Knowledge of Sarcoma. Ann Surg 1891, 14(3):199-220.
10. Coley W.B. II. Injury as a Causative Factor in Cancer (Continued). Ann Surg 1911, 53(5):615-650.
11. Bedognetti D., Wang E., Sertoli M.R., Marincola F.M. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010, 9(6):555-565.
12. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17(13):4550-4557.
13. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364(22):2119-2127.
14. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
15. Bedognetti D., Wang E., Sertoli M.R., F.M.M. Melanoma and biomarkers of immunoresponsiveness. Emerging therapeutics for melanoma 2012, In: "Emerging therapeutics for melanoma. FM Marincola PAaJKE, Future Science Group, 2011. Melanoma and biomarkers of immunoresponsiveness, Future Science Group.
16. Bedognetti D., Balwit J.M., Wang E., Disis M.L., Britten C.M., Delogu L.G., et al. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011, 9.
17. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
18. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17(7):2105-2116.
19. Atkins M.B., Mier J.W., Parkinson D.R., Gould J.A., Berkman E.M., Kaplan M.M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988, 318(24):1557-1563.
20. Mazumder A., Rosenberg S.A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984, 159(2):495-507.
21. Kirkwood J.M., Tarhini A.A., Panelli M.C., Moschos S.J., Zarour H.M., Butterfield L.H., et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008, 26(20):3445-3455.
22. Kirkwood J.M., Ernstoff M.S., Davis C.A., Reiss M., Ferraresi R., Rudnick S.A. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985, 103(1):32-36.
23. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254(5038):1643-1647.
24. Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176(5):1453-1457.
25. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002, 20(20):4169-4180.
26. Marincola F.M., Ferrone S. Immunotherapy of melanoma: the good news, the bad ones and what to do next. Semin Cancer Biol 2003, 13(6):387-389.
27. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181-273.
28. Marincola F.M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003, 24(6):335-342.
29. Wang E., Miller L.D., Ohnmacht G.A., Liu E.T., Marincola F.M. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000, 18(4):457-459.
30. Panelli M.C., Martin B., Nagorsen D., Wang E., Smith K., Monsurro V., et al. A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 2004, 177(3):124-131.
31. Panelli M.C., Stashower M.E., Slade H.B., Smith K., Norwood C., Abati A., et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007, 8(1):R8.
32. Panelli M.C., Wang E., Phan G., Puhlmann M., Miller L., Ohnmacht G.A., et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002, 3(7). RESEARCH0035.
33. Panelli M.C., White R., Foster M., Martin B., Wang E., Smith K., et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004, 2(1):17.
34. Weiss G.R., Grosh W.W., Chianese-Bullock K.A., Zhao Y., Liu H., Slingluff C.L., et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011, 17(23):7440-7450.
35. Wang E., Miller L.D., Ohnmacht G.A., Mocellin S., Perez-Diez A., Petersen D., et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62(13):3581-3586.
36. Carretero R., Wang E., Rodriguez A.I., Reinboth J., Ascierto M.L., Engle A.M., et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2011.
37. Imanguli M.M., Swaim W.D., League S.C., Gress R.E., Pavletic S.Z., Hakim F.T. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009, 113(15):3620-3630.
38. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001, 75(15):7059-7066.
39. He X.S., Ji X., Hale M.B., Cheung R., Ahmed A., Guo Y., et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006, 44(2):352-359.
40. Feld J.J., Nanda S., Huang Y., Chen W., Cam M., Pusek S.N., et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007, 46(5):1548-1563.
41. Nanda S., Havert M.B., Calderon G.M., Thomson M., Jacobson C., Kastner D., et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PloS one 2008, 3(10):e3442.
42. Asselah T., Bieche I., Narguet S., Sabbagh A., Laurendeau I., Ripault M.P., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008, 57(4):516-524.
43. Spivey T.L., Uccellini L., Ascierto M.L., Zoppoli G., De Giorgi V., Delogu L.G., et al. Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011, 9:174.
44. Zhao D.X., Hu Y., Miller G.G., Luster A.D., Mitchell R.N., Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002, 169(3):1556-1560.
45. Okamoto Y., Folco E.J., Minami M., Wara A.K., Feinberg M.W., Sukhova G.K., et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008, 102(2):218-225.
46. Costa C., Rufino R., Traves S.L., Lapa E.S.J.R., Barnes P.J., Donnelly L.E. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008, 133(1):26-33.
47. Kim M.J., Romero R., Kim C.J., Tarca A.L., Chhauy S., LaJeunesse C., et al. Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease. J Immunol 2009, 182(6):3919-3927.
48. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012, 30:677-706.
49. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011, 71(17):5601-5605.
50. Wang E., Worschech A., Marincola F.M. The immunologic constant of rejection. Trends Immunol 2008, 29(6):256-262.
51. Ascierto M.L., De Giorgi V., Liu Q.Z., Bedognetti D., Spivey T.L., Murtas D., et al. An immunologic portrait of cancer. J Transl Med 2011, 9.
52. Ascierto P.A., De Maio E., Bertuzzi S., Palmieri G., Halaban R., Hendrix M., et al. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011, 9:32.
53. Azimi F., Scolyer R.A., Rumcheva P., Moncrieff M., Murali R., McCarthy S.W., et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012, 30(21):2678-2683.
54. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29(15):1949-1955.
55. Hwang W.T., Adams S.F., Tahirovic E., Hagemann I.S., Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012, 124(2):192-198.
56. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
57. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353(25):2654-2666.
58. Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28(1):105-113.
59. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69(6):2685-2693.
60. Galon J., Fridman W.H., Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007, 67(5):1883-1886.
61. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138(4):1429-1440.
62. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29(6):610-618.
63. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27(35):5944-5951.
64. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71(4):1263-1271.
65. Ascierto M.L., De Giorgi V., Liu Q., Bedognetti D., Spivey T.L., Murtas D., et al. An immunologic portrait of cancer. J Transl Medicine 2011, in press.
66. Ascierto M.L., Kmieciak M., Idowu M.O., Manjili R., Zhao Y., Grimes M., et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012, 131(3):871-880.
67. McGray A.J., Bernard D., Hallett R., Kelly R., Jha M., Gregory C., et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 2012, 1(4):419-431.
68. Urosevic M., Maier T., Benninghoff B., Slade H., Burg G., Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003, 139(10):1325-1332.
69. Bedognetti D., Uccellini L., Wang E., Dudley M.E., Pos Z., Ascierto M.L., et al. Evaluation of CXCR3 and CCR5 Polymorphisms and Gene-Expression as Predictive Biomarkers of Clinical Response to Adoptive Therapy in Melanoma Patients. J Immunother 2010, 33(8):860.
70. Cotran R.S., Pober J.S., Gimbrone M.A., Springer T.A., Wiebke E.A., Gaspari A.A., et al. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988, 140(6):1883-1888.
71. Sabatino M., Kim-Schulze S., Panelli M.C., Stroncek D., Wang E., Taback B., et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009, 27(16):2645-2652.
72. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2(10):1096-1103.
73. Ohm J.E., Gabrilovich D.I., Sempowski G.D., Kisseleva E., Parman K.S., Nadaf S., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101(12):4878-4886.
74. Pockaj B.A., Sherry R.M., Wei J.P., Yannelli J.R., Carter C.S., Leitman S.F., et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994, 73(6):1731-1737.
75. Fisher B., Packard B.S., Read E.J., Carrasquillo J.A., Carter C.S., Topalian S.L., et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989, 7(2):250-261.
76. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother CII 2012, 61(7):1019-1031.
77. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (CII) 2012, 61(7):1019-1031.
78. Sarwal M., Chua M.S., Kambham N., Hsieh S.C., Satterwhite T., Masek M., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003, 349(2):125-138.
79. Schmidt M., Hellwig B., Hammad S., Othman A., Lohr M., Chen Z., et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012, 18(9):2695-2703.
80. Gajewski T., Meng Y., Harlin H. Chemokines expressed in melanoma metastases associated with T cell infiltration. J Clin Oncol 2007, 25.
81. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69(7):3077-3085.
82. Gajewski T.F., Fuertes M., Spaapen R., Zheng Y., Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011, 23(2):286-292.
83. Gajewski T.F., Zha Y., Thurner B., Schuler G. Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol 2009, 29(15).
84. Louahed O., Gruselle O., Gaulis S., Coche T., Eggermont A.M., Kruit W., et al. Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol 2008, 26.
85. Tahara H., Sato M., Thurin M., Wang E., Butterfield L.H., Disis M.L., et al. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009, 7:45.
86. Vansteenkiste J.F., Zielinski M., Dahabreh I.J., Linder A., Lehmann F., Gruselle O., et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26.
87. Sullivan R.J., Hoshida Y., Brunet J., Tahan S., Aldridge J., Kwabi C., et al. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol 2009, 27.
88. Sznol M. Molecular markers of response to treatment for melanoma. Cancer J 2011, 17(2):127-133.
89. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16(4):399-403.
90. Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204.
91. Muller A.J., Mandik-Nayak L., Prendergast G.C. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy 2010, 2(3):293-297.
92. Prendergast G.C., Chang M.Y., Mandik-Nayak L., Metz R., Muller A.J. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 2011, 18(15):2257-2262.
93. Scott G.N., DuHadaway J., Pigott E., Ridge N., Prendergast G.C., Muller A.J., et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009, 182(12):7509-7517.
94. Correale P., Rotundo M.S., Del Vecchio M.T., Remondo C., Migali C., Ginanneschi C., et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010, 33(4):435-441.
95. Frey D.M., Droeser R.A., Viehl C.T., Zlobec I., Lugli A., Zingg U., et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010, 126(11):2635-2643.
96. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27(2):186-192.
97. Ladoire S., Martin F., Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother CII. 2011, 60(7):909-918.
98. Yoon H.H., Orrock J.M., Foster N.R., Sargent D.J., Smyrk T.C., Sinicrope F.A. Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas. PloS one 2012, 7(8):e42274.
99. Roncador G., Brown P.J., Maestre L., Hue S., Martinez-Torrecuadrada J.L., Ling K.L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35(6):1681-1691.
100. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003, 112(9):1437-1443.
101. Le D.T., Ladle B.H., Lee T., Weiss V., Yao X., Leubner A., et al. CD8(+) Foxp3(+) tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Int J Cancer 2011, 129(3):636-647.
102. Brody J.R., Costantino C.L., Berger A.C., Sato T., Lisanti M.P., Yeo C.J., et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009, 8(12):1930-1934.
103. Prendergast G.C., Metz R., Muller A.J. IDO recruits Tregs in melanoma. Cell Cycle 2009, 8(12):1818-1819.
104. Beck K.E., Blansfield J.A., Tran K.Q., Feldman A.L., Hughes M.S., Royal R.E., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24(15):2283-2289.
105. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100(14):8372-8377.
106. Phan G.Q., Attia P., Steinberg S.M., White D.E., Rosenberg S.A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19(15):3477-3482.
107. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354(7):709-718.
108. Bouwhuis M.G., Suciu S., Collette S., Aamdal S., Kruit W.H., Bastholt L., et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009, 101(12):869-877.
109. Bouwhuis M.G., Suciu S., Testori A., Kruit W.H., Sales F., Patel P., et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 2010, 28(14):2460-2466.
110. Butterfield L.H., Comin-Anduix B., Vujanovic L., Lee Y., Dissette V.B., Yang J.Q., et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008, 31(3):294-309.
111. Butterfield L.H., Ribas A., Dissette V.B., Amarnani S.N., Vu H.T., Oseguera D., et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003, 9(3):998-1008.
112. Ribas A., Glaspy J.A., Lee Y., Dissette V.B., Seja E., Vu H.T., et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004, 27(5):354-367.
113. Ribas A., Timmerman J.M., Butterfield L.H., Economou J.S. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003, 24(2):58-61.
114. Disis M.L. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother CII. 2011, 60(3):433-442.
115. Uccellini L., De Giorgi V., Zhao Y., Tumaini B., Erdenebileg N., Dudley M.E., et al. IRF5 gene polymorphisms in melanoma. J Transl Med 2012, 10(1):170.
116. Monsurro V., Beghelli S., Wang R., Barbi S., Coin S., Di Pasquale G., et al. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med 2010, 8:10.
117. Spivey T.L., De Giorgi V., Zhao Y.D., Bedognetti D., Pos Z., Liu Q.Z., et al. The stable traits of melanoma genetics: an alternate approach to target discovery. Bmc Genomics 2012, 13.
118. Bedognetti D., Tomei S., Spivey S., De Giorgi V., Ascierto M.L., Wang E., et al. Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, (Suppl; abstr 8756).
119. De Giorgi V., Liu Q., Pos Z., Wunderlich J., Spivey T.L., Uccellini L., et al. Genotypic, Phenotypic and Functional Analysis of Melanoma. J Immunother 2011, 34:696. (abstract).
120. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352.
121. Emens L.A., Silverstein S.C., Khleif S., Marincola F.M., Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med 2012, 10:70.
122. Fox B.A., Schendel D.J., Butterfield L.H., Aamdal S., Allison J.P., Ascierto P.A., et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011, 9(1):214.
123. Galon J., Pages F., Marincola F.M., Thurin M., Trinchieri G., Fox B.A., et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1.
124. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12(4):298-306.
125. Ogino S., Galon J., Fuchs C.S., Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011, 8(12):711-719.
126. Muthuswamy R., Berk E., Junecko B.F., Zeh H.J., Zureikat A.H., Normolle D., et al. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012, 72(15):3735-3743.
127. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365(8):725-733.
128. Scholler J., Brady T.L., Binder-Scholl G., Hwang W.T., Plesa G., Hege K.M., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012, 4(132). 132ra53.
129. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17(10):1290-1297.
130. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012, 12(10):671-684.